Unilife to Showcase Broad Portfolio of Innovative, Differentiated Injectable Drug Delivery Systems at Pharmapack Europe

 Unilife to Showcase Broad Portfolio of Innovative, Differentiated Injectable
                  Drug Delivery Systems at Pharmapack Europe

Continued Expansion of Unilife's World-Class Commercial Development Team

PR Newswire

YORK, Pa., Feb. 11, 2013

YORK, Pa., Feb.11, 2013 /PRNewswire/ --Unilife Corporation ("Unilife" or
"Company") (NASDAQ: UNIS, ASX: UNS), a U.S. based designer, developer and
supplier of injectable drug delivery systems, today announced it will exhibit
at the Pharmapack Europe Annual Meeting in Paris, France between February
13^th and 14^th.

"Unilife is delighted to be attending Pharmapack Europe in Paris this week in
association with more than 3,000 other pharmaceutical and drug delivery
industry leaders," stated Mr. Michael Ratigan, Senior Vice President and Chief
Commercial Officer at Unilife. "The Unilife commercial development team will
be available throughout Pharmapack to speak with pharmaceutical companies
about how our broad portfolio of innovative and highly differentiated device
technologies can be leveraged to enable and enhance their injectable
therapies," Mr. Ratigan said.

In late-2012, Unilife expanded its commercial development team with the
appointment of Douglas Stout, Derek Giersch, Joseph Crusco as Senior Directors
of Commercial Development, and Jashin Gugnani as Director of Commercial
Development.

To support accelerating customer demand, this week Unilife has further
expanded its commercial team of world-class industry experts with the
appointment of Glenn Thorpe to the position of Vice-President of Commercial
Development. Mr. Thorpe joins Unilife from West Pharmaceutical Systems where
he was previously Vice-President of Strategic Market Development and
Vice-President and General Manager for Injection Systems. Prior to West, Mr.
Glenn was at BD Pharmaceutical Systems, where he held various commercial roles
with increasing levels of responsibility over a decade.

"We are delighted to welcome Glenn to Unilife's commercial development team,"
said Unilife's Chief Executive Officer, Alan Shortall. "Glenn has been serving
the injectable drug delivery needs of pharmaceutical companies for more than
16 years across a variety of senior roles in sales, business development and
strategic marketing. With his deep technical knowledge in the design,
development and commercial supply of prefilled syringes, needlestick safety
products and patient-self-administration systems, we believe Glenn is a great
addition to our world-class team. We look forward to having Glenn make a
successful debut for Unilife at Pharmapack Europe," Mr. Shortall concluded.

Unilife is located at booth 168 during Pharmapack Europe. To schedule an
appointment, please contact a member of the Unilife team or email
customer.service@unilife.com.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and
commercial supplier of injectable drug delivery systems. Unilife's broad
portfolio of proprietary device technologies includes prefilled syringes with
automatic needle retraction, drug reconstitution delivery systems,
auto-injectors, bolus injection devices and targeted delivery systems. Each of
these innovative and highly differentiated device platforms can be customized
by Unilife to address specific customer, drug and patient requirements.
Unilife's global headquarters and state-of-the-art manufacturing facilities
are located in York, PA. For more information, please visit www.unilife.com or
download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

Thispress release contains forward-looking statements. All statements that
address operating performance, events or developments that we expect or
anticipate will occur in the future are forward-looking statements.These
forward-looking statements are based on management's beliefs and assumptions
and on information currently available to our management. Our management
believes that these forward-looking statements are reasonable as and when
made. However, you should not place undue reliance on any such forward-looking
statements because such statements speak only as of the date when made. We do
not undertake any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as required by law. In addition, forward-looking statements
are subject to certain risks and uncertainties that could cause actual
results, events and developments to differ materially from our historical
experience and our present expectations or projections. These risks and
uncertainties include, but are not limited to, those described in "Item1A.
Risk Factors" and elsewhere inourAnnual Report on Form 10-Kand those
described from time to time in other reports which we file with the Securities
and Exchange Commission.

General: UNIS-G

Investor Contacts (US):   Analyst Enquiries Investor Contacts Media Contact
                                               (Australia)
Todd Fromer / Garth         Lynn Pieper     Jeff Carter   Eve McGrath
Russell
KCSA Strategic              Westwicke          Unilife           Rubenstein
Communications             Partners          Corporation     PR
P: + 1 212-682-6300      P: + 1             P: + 61 2 8346    P: + 1 212
                            415-202-5678      6500          843-8490



SOURCE Unilife Corporation

Website: http://www.unilife.com
 
Press spacebar to pause and continue. Press esc to stop.